8-K: Zoetis Q3 2025 Revenue Hits $2.4B, Net Income Up 6%

Zoetis reported third-quarter 2025 revenue of $2.4 billion, a 1% increase, with net income rising 6% to $721 million, while revising full-year revenue guidance.

Summary

• Third quarter 2025 revenue was $2.4 billion, an increase of 1% on a reported basis and 4% on an organic operational basis compared to Q3 2024.
• Net income for Q3 2025 was $721 million, or $1.63 per diluted share, increasing 6% and 9% respectively on a reported basis.
• Adjusted net income for Q3 2025 was $754 million, or $1.70 per diluted share, increasing 5% and 8% respectively on a reported basis, and 9% and 12% on an organic operational basis.
• U.S. segment revenue was $1.3 billion, a decrease of 2% on a reported basis but an increase of 3% on an organic operational basis.
• International segment revenue was $1.1 billion, a 3% increase on a reported basis and a 6% increase on an organic operational basis.
• Full year 2025 revenue guidance was revised to $9.400 $9.475 billion, with organic operational revenue growth of 5.5% to 6.5%.
• Full year 2025 guidance for organic operational growth in adjusted net income was narrowed to 5.5% to 7.0%.
• Full year 2025 guidance for diluted EPS on an adjusted basis was maintained at $6.30 to $6.40.

Sentiment

Score: 7

Explanation: Zoetis delivered solid organic operational growth in Q3 2025 and achieved significant regulatory milestones, demonstrating strong execution and a robust pipeline. However, the downward revision of full-year revenue and adjusted net income guidance, attributed to broader macro trends, introduces a degree of caution, even though adjusted EPS guidance was maintained. The long-term outlook remains positive due to continuous innovation.

Positives

• Achieved 4% organic operational revenue growth and 9% organic operational growth in adjusted net income for Q3 2025.
• Reported net income increased 6% and diluted EPS increased 9% on a reported basis for Q3 2025.
• Secured significant regulatory milestones, including new product approvals and geographic expansions across various products and species.
• Received approval in Canada for Lenivia, the first long-acting monoclonal antibody to alleviate OA pain in dogs for up to three months with one injection, with EU marketing authorization expected in Q4 2025.
• Portela, the first monoclonal antibody therapy with a three-month dosing interval for OA pain in cats, received marketing authorization in the EU.
• Expanded key dermatology offerings with Apoquel Chewable approval in Chile and Cytopoint labeling for allergic dermatitis in Brazil.
• Simparica Trio received approval in Brazil and gained new label indications in Australia (heartworm microfilaria, A. aegypti mosquitoes), Canada (flea tapeworm prevention), and the UK (lungworm disease).
• Expanded the new premium point-of-care hematology analyzer, Vetscan Opticell, into the EU following a successful U.S. launch.
• Received conditional FDA approval for Dectomax-CA1 Injectable for prevention and treatment of New World screwworm myiasis in cattle, a first-of-its-kind product.
• Synovex Primer received additional claims approval in Canada and Mexico for increasing weight gain in beef cattle.
• Received approval in the UK for a needle-free microdose of Suvaxyn PRRS vaccine for porcine respiratory and reproductive syndrome.
• U.S. livestock products showed strong 14% organic operational growth, driven by improved supply of ceftiofur products and growth in vaccines.
• International companion animal products grew 4% operationally, driven by parasiticides and dermatology products.
• International livestock products increased 8% on an organic operational basis with broad-based growth across all core species.
• Maintained full year 2025 guidance for adjusted diluted EPS at $6.30 to $6.40 despite revenue guidance revision.

Negatives

• Reported revenue growth of 1% in Q3 2025 was modest.
• U.S. segment revenue decreased 2% on a reported basis for Q3 2025.
• Sales of monoclonal antibody (mAb) products for osteoarthritis (OA) pain, Librela for dogs and Solensia for cats, declined in the U.S.
• U.S. livestock products declined 9% on a reported basis due to the divestiture of the medicated feed additive (MFA) product portfolio and related assets.
• International livestock products declined 2% on a reported basis due to the divestiture of the MFA product portfolio and related assets.
• Full year 2025 revenue guidance was revised downwards to $9.400 $9.475 billion from the previous $9.450 $9.600 billion.
• Full year 2025 organic operational revenue growth guidance was lowered from 6.5% to 8% to 5.5% to 6.5%.
• Full year 2025 adjusted net income guidance was revised downwards to $2.800 $2.840 billion from the previous $2.825 $2.875 billion.
• Full year 2025 organic operational growth in adjusted net income guidance was narrowed to 5.5% to 7.0% from 5.5% to 7.5%.

Risks

• Broader macro trends and the operational environment could impact future financial performance.
• Disruptions in the global supply chain may affect product availability and costs.
• Competition from existing and new products could impact market share and pricing.
• The ability to successfully integrate new businesses and realize the financial impact of acquisitions is subject to uncertainties.
• Fluctuations in foreign exchange rates, changes in tax rates, tariffs, and tax regimes could affect financial results.

Future Outlook

Zoetis expects to receive a significant product approval in a major market every year for the next several years, driven by lifecycle innovation, geographic expansion, and disruptive innovation. The company will host an Innovation webcast on December 2, 2025, to provide updates on its pipeline and strategic approach for long-term growth. Full-year 2025 revenue and adjusted net income guidance has been revised downwards based on broader macro trends and the operational environment, while adjusted diluted EPS guidance has been maintained, reflecting continued disciplined execution.

Management Comments

• "We reported 4% organic operational revenue growth and 9% growth in adjusted net income on an organic operational basis, thanks to the relentless focus and consistent execution of our colleagues across the world."
• "While growth moderated in the third quarter in line with our expectations, we achieved significant regulatory milestones, including major new product approvals, geographic expansions and differentiating lifecycle innovations across products and species."
• "With our manufacturing excellence, strong customer relationships and a robust pipeline, we are well positioned to advance animal care, bring new products to market and deliver sustainable growth and value for our shareholders."

Industry Context

The animal health industry continues to demonstrate resilience and demand for innovative solutions across both companion animals and livestock. Zoetis' focus on developing and expanding its portfolio in areas like long-acting pain management, advanced parasiticides, and point-of-care diagnostics aligns with key industry trends. The moderation of growth observed in Q3, as acknowledged by the CEO, suggests that broader macro trends are influencing the sector, but Zoetis' robust pipeline and strategic market expansions position it to navigate these dynamics and maintain its leadership.

Comparison to Industry Standards

• Zoetis' 4% organic operational revenue growth and 9% organic operational adjusted net income growth in Q3 2025 indicate strong performance relative to the generally stable growth rates typical of the mature animal health pharmaceutical industry.
• The approvals of Lenivia and Portela, both long-acting monoclonal antibodies for osteoarthritis pain in dogs and cats respectively, position Zoetis as a leader in advanced pain management, potentially offering a competitive advantage over existing daily or shorter-acting treatments from competitors.
• The expanded label indications for Simparica Trio, including the first heartworm preventative in Australia with microfilaricidal activity and the only canine combination parasiticide to prevent flea tapeworm infections in Canada, demonstrate a differentiated product offering compared to other broad-spectrum parasiticides on the market.
• The launch of Vetscan Opticell, an AI-powered hematology analyzer, signifies Zoetis' commitment to innovation in veterinary diagnostics, providing lab-quality results at the point-of-care, which could set a new benchmark for efficiency and accuracy against traditional in-clinic or external lab services.
• The conditional FDA approval for Dectomax-CA1 Injectable for New World screwworm prevention and treatment in cattle addresses a specific and urgent threat, providing a unique solution that may not have direct comparables in the U.S. livestock parasite control market.

Stakeholder Impact

• Shareholders: Potential for sustainable growth and value creation through new product launches and disciplined execution, but also subject to impacts from revised full-year guidance.
• Veterinarians and Pet Owners: Will benefit from access to new and expanded innovative products for animal health, including long-acting pain relief, advanced parasiticides, and efficient point-of-care diagnostics.
• Livestock Producers: Will gain access to new solutions for critical health threats and improved products for growth and disease prevention.
• Employees: Continued focus on execution and potential impacts from the realignment of the U.S. field structure aimed at improving efficiency and customer experience.

Next Steps

• Host an Innovation webcast on Tuesday, December 2, 2025, at 8:30 a.m. ET to provide investors with updates and progress related to its pipeline and strategic approach.
• Anticipate marketing authorization for Lenivia in the EU in the fourth quarter of 2025.
• Expect to launch Lenivia in Canada in 2026.
• Anticipate making Lenivia commercially available in the EU in 2026.
• Anticipate making Portela commercially available in the EU in 2026.
• Continue to expand differentiated dermatology offerings and Simparica franchises around the world.
• Evolve U.S. go-to-market strategy, including realigning the U.S. field structure, to reinforce market leadership and better serve customers.

Key Dates

Recommendation

While Zoetis demonstrated strong organic operational performance and a robust pipeline with significant regulatory approvals, the downward revision of full-year revenue and adjusted net income guidance introduces a degree of uncertainty. The company's ability to maintain adjusted EPS guidance is positive, but the macro environment concerns warrant a cautious approach. Investors should hold to observe how the company navigates the broader macro trends and executes on its revised guidance and pipeline initiatives.

Keywords

Zoetis, ZTS, Animal Health, Veterinary Medicine, Pet Care, Livestock, Companion Animals, Q3 2025 Earnings, Financial Results, Guidance, Monoclonal Antibody, Parasiticides, Dermatology, Diagnostics, Vaccines